

Data Sheet

WWW. UREIKO-CHEM. COM

Global Supplier of Chemical Probes, Inhibitors & Agonists

Product Name :Werner syndrome RecQ helicase-IN-2

 Cat.No.
 :URK-V2494

 CAS No.
 :2869954-51-6

 Molecular Formula
 : $C_{32}H_{34}F_3N_9O_5$

 Molecular Weight
 :681.66

Target : Solubility :

Biological Activity

Werner syndrome RecQ helicase-IN-2 (WRN-IN-2) is a promising target for cancer therapy due to its role in the progression of cancer cells.

WRN-IN-2 is a protein involved in DNA damage repair and telomere maintenance. Dysfunctional WRN-IN-2 can lead to cancer and premature aging. In cancer, WRN-IN-2's function is to promote tumor cell survival, resistance to chemotherapy, and metastasis. Therefore, targeting WRN-IN-2 shows potential in cancer treatment.

WRN-IN-2 inhibitors act by blocking the activity of the protein and forcing cancer cells into replicative stress, which impairs their DNA repair function and ultimately leads to apoptosis.

Several WRN-IN-2 inhibitors have been identified, and their feasibility in the treatment of cancer is under investigation. The most promising inhibitors belong to the benzodiazepine class and show high potency and selectivity for WRN inhibition.

Encouraging results have been reported in preliminary studies, and it is speculated that WRN-IN-2 inhibitors could have a synergistic effect with other anti-cancer agents.

References

- 1. Kim HJ, Min SK, Ahn JY, Kwon T. WRN inhibitor has potential as a targeted therapy for colorectal cancer. Int J Mol Sci. 2018;19(2):353.
- 2. Trujillo JP, Miret JJ, Pérez-Soler R, et al. Identification and characterization of novel inhibitors for Werner helicase. Oncotarget. 2017;8(56):95699-95714.
- 3. Chen X, Ling JJ, Pena LA, et al. The WRN inhibitor IBR612 suppresses the growth of triple-negative breast cancer cells. BMC Cancer. 2019;19(1):416.

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, we do not provide products and services for any personal use!